Protalix Biotherapeutics, Inc. (PLX) Completes Phase III Trial for Gaucher Disease Treatment
Protalix Biotherapeutics, Inc. continues to make headlines with its innovative compound, a recombinant form of glucocerebrosidase (prGCD). Last week, the company released that its compound had received the FDA’s Orphan Drug Donation. Yesterday, the company announced that they have completed the Phase III trial for prGCD. The compound is designed to treat Gaucher disease, a rare and serious lysosomal storage disorder in humans with debilitating symptoms. Protalix plans to release top-line results from this study in October 2009, but has shed light on a few details; the trial enrolled 31 patients across Europe, North America, South America, Israel and South…